First LP to introduce colour-coded and cannabis variety specific softgel capsules for
safe and easy medication management

MARKHAM, ON, Feb. 6, 2018 /CNW/ - MedReleaf Corp. (TSX:LEAF) ("MedReleaf" or the "Company"), Canada's first and only ISO 9001 and ICH-GMP certified cannabis producer, today announced that it has received Health Canada approval for the sale of its cannabis oil softgel capsules, becoming the first licensed producer ("LP") to bring colour-coded and cannabis variety-specific softgel capsules to market and the only LP to manufacture softgel capsules from a certified ISO and GMP facility.

"Orally ingested softgel capsules give prescribing physicians and patients precise dosing in a familiar and convenient medicinal form factor. These products provide access to cannabis for an under-served patient community more comfortable taking their medication in a traditional capsule rather than by oil or through vapourizers," said Robert Gora, Senior Director of Physician Outreach. "As part of MedReleaf's ongoing focus on patient safety, our softgel capsules are uniquely colour-coded to allow patients to easily differentiate between the specific cultivar or type of oil product that they are consuming, letting patients more safely manage their medication."

"Our product development teams continue to set the standard for innovation and quality in our industry with pharmaceutical-grade softgel capsules that faithfully capture both cannabinoid and terpenes profiles of our award-winning varieties. The addition of softgel capsules to our product line will enhance our efforts to build physician support for medical cannabis and are more cost effective to produce, easier to swallow, and have a longer shelf-life than standard oil capsules," added Neil Closner, CEO of MedReleaf.

MedReleaf's softgel capsules will be categorized by four different colours. This colour colding ensures that patients will know the specific cultivar or type of oil product they are consuming:

• Blue for indicas (nighttime)
• Yellow for sativas (daytime)
• Colourless for capsules without THC (CBD only)
• Purple for balanced products (featuring both THC & CBD)

Production of MedReleaf's softgel capsules has begun and will be available for order in the following varieties in the coming weeks:

MedReleaf patients and health care professionals are encouraged to visit www.MedReleaf.com to find out more and to order product.

About MedReleaf Corp.

Voted Top Licensed Producer at the 2017 Lift Canadian Cannabis Awards, MedReleaf is an R&D-driven company dedicated to innovation, operational excellence and the production of top-quality cannabis.  Sourced from around the world and carefully cultivated in one of two state of the art ICH-GMP and ISO 90001 certified facilities in Ontario, the Company delivers a variety of premium products for the global medical market and is committed to serving the therapeutic needs of its medical patients and providing a compelling product assortment for the adult-use recreational consumer. 

For more information on MedReleaf, its products, research and how the company is helping patients #livefree, please visit MedReleaf.com or follow @medreleaf

Forward Looking Statements

This press release contains "forward-looking information" within the meaning of applicable Canadian securities legislation which are based upon MedReleaf's current internal expectations, estimates, projections, assumptions and beliefs and views of future events. Forward-looking information can be identified by the use of forward-looking terminology such as "expect", "likely", "may", "will", "should", "intend", "anticipate", "potential", "proposed", "estimate" and other similar words, including negative and grammatical variations thereof, or statements that certain events or conditions "may", "would" or "will" happen, or by discussions of strategy. Forward-looking information include estimates, plans, expectations, opinions, forecasts, projections, targets, guidance or other statements that are not statements of fact.

Any forward-looking information speaks only as of the date on which it is made, and, except as required by law, MedReleaf does not undertake any obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise. New factors emerge from time to time, and it is not possible for MedReleaf to predict all such factors. When considering these forward-looking statements, readers should keep in mind the risk factors and other cautionary statements in MedReleaf's Annual Information Form dated June 27, 2017 and filed with the applicable Canadian securities regulatory authorities on SEDAR at www.sedar.com. The risk factors and other factors noted in MedReleaf's Annual Information Form could cause actual events or results to differ materially from those described in any forward-looking information.

SOURCE MedReleaf Corp.

View original content: http://www.newswire.ca/en/releases/archive/February2018/06/c7043.html